The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells

Hendrik W. Van Deventer, Joseph E. Burgents, Qing Ping Wu, Rita Marie T Woodford, W. June Brickey, Irving C. Allen, Erin McElvania-Tekippe, Jonathan S. Serody, Jenny P Y Ting

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The inflammasome is a proteolysis complex that generates the active forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18. Inflammasome activation is mediated by NLR proteins that respond to microbial and nonmicrobial stimuli. Among NLRs, NLRP3 senses the widest array of stimuli and enhances adaptive immunity. However, its role in antitumor immunity is unknown. Therefore, we evaluated the function of the NLRP3 inflammasome in the immune response using dendritic cell vaccination against the poorly immunogenic melanoma cell line B16-F10. Vaccination of Nlrp3-/- mice led to a relative 4-fold improvement in survival relative to control animals. Immunity depended on CD8+ T cells and exhibited immune specificity and memory. Increased vaccine efficacy in Nlrp3-/- hosts did not reflect differences in dendritic cells but rather differences in myeloid-derived suppressor cells (MDSC). Although Nlrp3 was expressed in MDSCs, the absence of Nlrp3 did not alter either their functional capacity to inhibit T cells or their presence in peripheral lymphoid tissues. Instead, the absence of Nlrp3 caused a 5-fold reduction in the number of tumor-associated MDSCs found in host mice. Adoptive transfer experiments also showed that Nlrp3-/- MDSCs were less efficient in reaching the tumor site. Depleting MDSCs with an anti-Gr-1 antibody increased the survival of tumor-bearing wild-type mice but not Nlrp3-/- mice. We concluded that Nlrp3 was critical for accumulation of MDSCs in tumors and for inhibition of antitumor T-cell immunity after dendritic cell vaccination. Our findings establish an unexpected role for Nlrp3 in impeding antitumor immune responses, suggesting novel approaches to improve the response to antitumor vaccines by limiting Nlrp3 signaling.

Original languageEnglish (US)
Pages (from-to)10161-10169
Number of pages9
JournalCancer Research
Volume70
Issue number24
DOIs
StatePublished - Dec 15 2010

Fingerprint

Inflammasomes
Vaccines
Dendritic Cells
Immunity
Neoplasms
Vaccination
T-Lymphocytes
Interleukin-18
Adoptive Transfer
Adaptive Immunity
Lymphoid Tissue
Interleukin-1
Proteolysis
Myeloid-Derived Suppressor Cells
Melanoma
Cytokines
Cell Line
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Deventer, H. W., Burgents, J. E., Wu, Q. P., Woodford, R. M. T., Brickey, W. J., Allen, I. C., ... Ting, J. P. Y. (2010). The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Research, 70(24), 10161-10169. https://doi.org/10.1158/0008-5472.CAN-10-1921

The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. / Van Deventer, Hendrik W.; Burgents, Joseph E.; Wu, Qing Ping; Woodford, Rita Marie T; Brickey, W. June; Allen, Irving C.; McElvania-Tekippe, Erin; Serody, Jonathan S.; Ting, Jenny P Y.

In: Cancer Research, Vol. 70, No. 24, 15.12.2010, p. 10161-10169.

Research output: Contribution to journalArticle

Van Deventer, Hendrik W. ; Burgents, Joseph E. ; Wu, Qing Ping ; Woodford, Rita Marie T ; Brickey, W. June ; Allen, Irving C. ; McElvania-Tekippe, Erin ; Serody, Jonathan S. ; Ting, Jenny P Y. / The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. In: Cancer Research. 2010 ; Vol. 70, No. 24. pp. 10161-10169.
@article{ed59b1eb4f1d4a7bb96e7a8d2db91d06,
title = "The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells",
abstract = "The inflammasome is a proteolysis complex that generates the active forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18. Inflammasome activation is mediated by NLR proteins that respond to microbial and nonmicrobial stimuli. Among NLRs, NLRP3 senses the widest array of stimuli and enhances adaptive immunity. However, its role in antitumor immunity is unknown. Therefore, we evaluated the function of the NLRP3 inflammasome in the immune response using dendritic cell vaccination against the poorly immunogenic melanoma cell line B16-F10. Vaccination of Nlrp3-/- mice led to a relative 4-fold improvement in survival relative to control animals. Immunity depended on CD8+ T cells and exhibited immune specificity and memory. Increased vaccine efficacy in Nlrp3-/- hosts did not reflect differences in dendritic cells but rather differences in myeloid-derived suppressor cells (MDSC). Although Nlrp3 was expressed in MDSCs, the absence of Nlrp3 did not alter either their functional capacity to inhibit T cells or their presence in peripheral lymphoid tissues. Instead, the absence of Nlrp3 caused a 5-fold reduction in the number of tumor-associated MDSCs found in host mice. Adoptive transfer experiments also showed that Nlrp3-/- MDSCs were less efficient in reaching the tumor site. Depleting MDSCs with an anti-Gr-1 antibody increased the survival of tumor-bearing wild-type mice but not Nlrp3-/- mice. We concluded that Nlrp3 was critical for accumulation of MDSCs in tumors and for inhibition of antitumor T-cell immunity after dendritic cell vaccination. Our findings establish an unexpected role for Nlrp3 in impeding antitumor immune responses, suggesting novel approaches to improve the response to antitumor vaccines by limiting Nlrp3 signaling.",
author = "{Van Deventer}, {Hendrik W.} and Burgents, {Joseph E.} and Wu, {Qing Ping} and Woodford, {Rita Marie T} and Brickey, {W. June} and Allen, {Irving C.} and Erin McElvania-Tekippe and Serody, {Jonathan S.} and Ting, {Jenny P Y}",
year = "2010",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-10-1921",
language = "English (US)",
volume = "70",
pages = "10161--10169",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells

AU - Van Deventer, Hendrik W.

AU - Burgents, Joseph E.

AU - Wu, Qing Ping

AU - Woodford, Rita Marie T

AU - Brickey, W. June

AU - Allen, Irving C.

AU - McElvania-Tekippe, Erin

AU - Serody, Jonathan S.

AU - Ting, Jenny P Y

PY - 2010/12/15

Y1 - 2010/12/15

N2 - The inflammasome is a proteolysis complex that generates the active forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18. Inflammasome activation is mediated by NLR proteins that respond to microbial and nonmicrobial stimuli. Among NLRs, NLRP3 senses the widest array of stimuli and enhances adaptive immunity. However, its role in antitumor immunity is unknown. Therefore, we evaluated the function of the NLRP3 inflammasome in the immune response using dendritic cell vaccination against the poorly immunogenic melanoma cell line B16-F10. Vaccination of Nlrp3-/- mice led to a relative 4-fold improvement in survival relative to control animals. Immunity depended on CD8+ T cells and exhibited immune specificity and memory. Increased vaccine efficacy in Nlrp3-/- hosts did not reflect differences in dendritic cells but rather differences in myeloid-derived suppressor cells (MDSC). Although Nlrp3 was expressed in MDSCs, the absence of Nlrp3 did not alter either their functional capacity to inhibit T cells or their presence in peripheral lymphoid tissues. Instead, the absence of Nlrp3 caused a 5-fold reduction in the number of tumor-associated MDSCs found in host mice. Adoptive transfer experiments also showed that Nlrp3-/- MDSCs were less efficient in reaching the tumor site. Depleting MDSCs with an anti-Gr-1 antibody increased the survival of tumor-bearing wild-type mice but not Nlrp3-/- mice. We concluded that Nlrp3 was critical for accumulation of MDSCs in tumors and for inhibition of antitumor T-cell immunity after dendritic cell vaccination. Our findings establish an unexpected role for Nlrp3 in impeding antitumor immune responses, suggesting novel approaches to improve the response to antitumor vaccines by limiting Nlrp3 signaling.

AB - The inflammasome is a proteolysis complex that generates the active forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18. Inflammasome activation is mediated by NLR proteins that respond to microbial and nonmicrobial stimuli. Among NLRs, NLRP3 senses the widest array of stimuli and enhances adaptive immunity. However, its role in antitumor immunity is unknown. Therefore, we evaluated the function of the NLRP3 inflammasome in the immune response using dendritic cell vaccination against the poorly immunogenic melanoma cell line B16-F10. Vaccination of Nlrp3-/- mice led to a relative 4-fold improvement in survival relative to control animals. Immunity depended on CD8+ T cells and exhibited immune specificity and memory. Increased vaccine efficacy in Nlrp3-/- hosts did not reflect differences in dendritic cells but rather differences in myeloid-derived suppressor cells (MDSC). Although Nlrp3 was expressed in MDSCs, the absence of Nlrp3 did not alter either their functional capacity to inhibit T cells or their presence in peripheral lymphoid tissues. Instead, the absence of Nlrp3 caused a 5-fold reduction in the number of tumor-associated MDSCs found in host mice. Adoptive transfer experiments also showed that Nlrp3-/- MDSCs were less efficient in reaching the tumor site. Depleting MDSCs with an anti-Gr-1 antibody increased the survival of tumor-bearing wild-type mice but not Nlrp3-/- mice. We concluded that Nlrp3 was critical for accumulation of MDSCs in tumors and for inhibition of antitumor T-cell immunity after dendritic cell vaccination. Our findings establish an unexpected role for Nlrp3 in impeding antitumor immune responses, suggesting novel approaches to improve the response to antitumor vaccines by limiting Nlrp3 signaling.

UR - http://www.scopus.com/inward/record.url?scp=78650360196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650360196&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1921

DO - 10.1158/0008-5472.CAN-10-1921

M3 - Article

C2 - 21159638

AN - SCOPUS:78650360196

VL - 70

SP - 10161

EP - 10169

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -